Results 141 to 150 of about 130,928 (189)

Pharmacological enhancement of protease inhibitors with ritonavir: an update

Expert Review of Clinical Pharmacology, 2008
Advances in HIV treatment since the approval of the first antiretroviral (ARV) medication have occurred at a rapid pace. However, resistance to these medications can occur quickly owing to inadequate plasma concentrations resulting from poor adherence related to intolerable drug toxicities and complex dosing schedules.
Kristin Busse, Scott Penzak
openalex   +4 more sources

Updated clinical pharmacologic considerations for HIV-1 protease inhibitors

Current HIV/AIDS Reports, 2004
Many data associate low protease inhibitor plasma concentrations with suboptimal virologic responses, whereas fewer data associate high plasma concentrations with toxicity. Knowledge of relationships between concentrations and virologic response is important because significant variability in concentrations exists among patients.
Peter L. Anderson, Courtney V. Fletcher
openalex   +4 more sources

The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy

Expert Opinion on Investigational Drugs, 2003
Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. Complex metabolism by the cytochrome P450 system (particularly the 3A4 isoenzyme), action of membrane drug transporter elements (such as P-glycoprotein and ...
Stephen Becker
openalex   +4 more sources

Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes

Drug Metabolism and Disposition, 2000
HIV protease inhibitors have proven remarkably effective in treating HIV-1 infection. However, some tissues such as the brain and testes (sanctuary sites) are possibly protected from exposure to HIV protease inhibitors due to drug entry being limited by the membrane efflux transporter P-glycoprotein, located in the capillary endothelium.
Edna F. Choo, Brenda F. Leake, Christoph Wandel, Hitoshi Imamura, Alastair J.J. Wood, G. Wilkinson, Richard B. Kim   +6 more
openalex   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Clinical pharmacology of HIV protease inhibitors in pregnancy

Current Opinion in HIV and AIDS, 2008
The use of highly active antiretroviral therapy during pregnancy has reduced the prevalence HIV of mother-to-child transmission (MTCT) dramatically. At present, the recommended first-line treatment for prevention of MTCT in developed countries is protease inhibitor-based highly active antiretroviral therapy.
Lugt, J. van der, Colbers, A., Burger, D.M.   +2 more
openaire   +4 more sources

HIV Protease Inhibitors in Pregnancy

Drugs, 2013
The impact of antiretroviral therapy (ART) on the natural history of HIV-1 infection has resulted in dramatic reductions in disease-associated morbidity and mortality. Additionally, the epidemiology of HIV-1 infection worldwide is changing, as women now represent a substantial proportion of infected adults.
Nisha Andany, Mona Loutfy, Mona Loutfy
openaire   +3 more sources

ChemInform Abstract: Synthesis and Pharmacological Evaluation of Sulfone Substituted HIV Protease Inhibitors.

ChemInform, 1997
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
R. R. Hinshaw, Gordon L. Bundy, Strohbach Joseph Walter, Theresa M. Schwartz, Johnson Paul D, Harvey Irving Skulnick, J. C. Lynn, Thomas J. Raub, Suvit Thaisrivongs, Paul K. Tomich, L. N. Toth, G. E. Padbury, Kong Teck Chong   +12 more
openaire   +3 more sources

Optimal therapies of a virus replication model with pharmacological delays based on reverse transcriptase inhibitors and protease inhibitors

Journal of Physics A: Mathematical and Theoretical, 2017
A short delay in the pharmacological effect on account of the time required for drug absorption, distribution, and penetration into target cells after application of any anti-viral drug, is defined by the pharmacological delay (Herz et al 1996 Proc. Natl Acad. Sci. USA 93 7247–51).
Changguo Li, Yongzhen Pei, Xiyin Liang
openaire   +2 more sources

The intracellular pharmacology of the antiretroviral protease inhibitors in a clinical setting.

, 2004
Jennifer Lynn Ford
openalex   +2 more sources

Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis

Journal of Gastroenterology, 2013
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is the most frequent complication of ERCP. Several meta-analyses have examined the effects of protease inhibitors (gabexate mesilate, ulinastatin, and nafamostat mesilate) and non-steroidal anti-inflammatory drugs (NSAIDs) on post-ERCP pancreatitis, but the results have been ...
Tooru Shimosegawa, Muneki Igarashi, Hiroki Yuhara, Masami Ogawa, Tetsuya Mine, Yoshiaki Kawaguchi   +5 more
openaire   +3 more sources